UNSPSC 51385603: Choline salicylate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C7H5O3.C5H14NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KD510K1IQW, chemically known as 2-hydroxy-n,n,n-trimethylethanaminium salt with 2-hydroxybenzoic acid (1:1) but generally known as choline salicylate, which bears US NIH Compound Identifier 16213. European Medicines Agency schedules Choline salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06219MIG.

UNSPSC 51385603 Choline salicylate is a Commodity code that in recent state and local procurement activity covers the supply of pharmaceutical products, naloxone, drug deactivation systems, and over-the-counter medicines to government health agencies and cooperative purchasing consortia. The code appears in practice to function as a catch-all taxonomy marker for pharmaceutical and health-related product procurement rather than a precise descriptor of choline salicylate specifically. State and local buyers issuing under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances coordinating procurement across multiple jurisdictions and member agencies. Vendors supplying under the code must typically meet cGMP certification, DEA and FDA compliance, E-Verify employment verification, drug-free workplace certification, and substantial insurance requirements including commercial general liability and professional liability coverage. The structure of recent solicitations emphasizes either direct county procurement or participation in multistate cooperative frameworks that leverage authorized wholesaler networks to reach multiple government entities simultaneously.

Recent activity appears concentrated in Florida and Texas, with multistate cooperative reach through Minnesota's MMCAP framework spanning Oregon and other participating states. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, closing July 26, 2023 (note: deadline date appears inconsistent with posting date). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription fulfillment models outside traditional PBM and wholesaler channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic pharmaceuticals and OTC products with March 26, 2026 deadline, requiring vendors to establish relationships with AmerisourceBergen, Cardinal Health, and Morris & Dickson as authorized distributors, with contract effectiveness July 1, 2026. The MMCAP solicitation weights price competitiveness at 75 percent and imposes a 3 percent administrative fee on all purchases.